Merck & Co Deal Validates Complix's Cell-Penetrating Protein Scaffold Platform
This article was originally published in Scrip
Complix, a private Belgian biotech company developing novel protein therapeutics, has secured Merck & Co Inc. as its first big name pharma partner. Complix will use its 'Alphabody' platform to deliver CPABs (cell-penetrating Alphabodies) against two undisclosed intracellular cancer targets suggested by Merck.
You may also be interested in...
The UK's main reimbursement bodies made a series of decisions this week that were broadly favorable and largely focused on oncology medicines.
While troubled Valeant was divesting iNova to private equity investors, Novartis announced a pair of oncology-focused deals, out-licensing a brain cancer drug to Midatech and partnering with IBM Watson Health to optimize breast cancer treatment.
Astellas and Pfizer have amended the PROSPER trial protocol in a bid to position Xtandi ahead of Zytiga in the early stage prostate cancer market.